Crossmark

Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Crossref DOI link: https://doi.org/10.1186/s13052-022-01272-z

Published Online: 2022-05-16

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Novembre, Elio

Tosca, Mariangela

Caffarelli, Carlo https://orcid.org/0000-0001-7710-6995
Calvani, Mauro

Cardinale, Fabio

Castagnoli, Riccardo

Chiappini, Elena

Cravidi, Claudio

Del Giudice, Michele Miraglia

Duse, Marzia

Licari, Amelia

Manti, Sara

Martelli, Alberto

Ricci, Giampaolo

Pingitore, Giuseppe

Marseglia, Gian Luigi
Funding

Funding for this research was provided by:

SIAIP
License Information

Text and Data Mining valid from 2022-05-16

Version of Record valid from 2022-05-16
More Information

Article History

Received: 24 February 2022

Accepted: 4 May 2022

First Online: 16 May 2022

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests to disclose in relation to this paper.

Document is current

Any future updates will be listed below